Horizon Therapeutics is focused on researching, developing and commercializing medicines that address the needs for people with rare and rheumatic diseases. Co. has two segments, the orphan segment and the inflammation segment. The Orphan segment includes: TEPEZZA, which is indicated for the treatment of thyroid eye diseas; KRYSTEXXA, which is indicated for the treatment of uncontrolled gout; and PROCYSBI, which is indicated for nephropathic cystinosis. The Inflammation segment includes: PENNSAID 2% w/w, which is indicated for the treatment of pain of osteoarthritis (OA), of the knee(s); and DUEXIS, which is indicated for the relief of signs and symptoms of rheumatoid arthritis and OA. When considering the Horizon Therapeutics Plc stock dividend history, we have taken known splits into account, such that the HZNP dividend history is presented on a split-adjusted ("apples to apples") basis. Horizon Therapeutics Plc dividend history is presented both in graphical/chart form, and as a HZNP dividend history data table along the right-hand column.
|
HZNP Stock Dividend HistoryThe HZNP dividend history graphic shown above is presented after taking into consideration any known stock split occurrences, in order to present the most directly comparable HZNP historical dividend comparison possible. Historical dividends, when charted graphically, can reveal the long-term variability and/or growth within the HZNP dividend history record. Also see the HZNP stock dividend history data table along the right-hand column below. |
|
|
Hold (2.00 out of 4) 100th percentile
(ranked higher than approx. 100% of all stocks covered)
Analysts' Target Price: HZNP Forecast Based on data provided by Zacks Investment Research via Quandl.com |